Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Operating Leases (2020 - 2025)

Adma Biologics' Operating Leases history spans 6 years, with the latest figure at $6.6 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 22.37% year-over-year to $6.6 million; the TTM value through Dec 2025 reached $6.6 million, down 22.37%, while the annual FY2025 figure was $6.6 million, 22.37% down from the prior year.
  • Operating Leases reached $6.6 million in Q4 2025 per ADMA's latest filing, down from $9.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $10.9 million in Q2 2022 to a low of $6.6 million in Q4 2025.
  • Average Operating Leases over 5 years is $9.1 million, with a median of $9.3 million recorded in 2025.
  • Peak YoY movement for Operating Leases: surged 72.18% in 2021, then decreased 22.37% in 2025.
  • A 5-year view of Operating Leases shows it stood at $7.5 million in 2021, then skyrocketed by 43.44% to $10.7 million in 2022, then dropped by 8.64% to $9.8 million in 2023, then fell by 12.46% to $8.6 million in 2024, then decreased by 22.37% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Operating Leases are $6.6 million (Q4 2025), $9.4 million (Q3 2025), and $9.3 million (Q2 2025).